Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia; Heart Failure Pharmacology, Baker Heart & Diabetes Institute, Melbourne, VIC 3004, Australia.
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
Pharmacol Ther. 2019 Jun;198:20-33. doi: 10.1016/j.pharmthera.2019.01.003. Epub 2019 Jan 22.
The adenosine A receptor (AAR) is one of four adenosine receptor subtypes belonging to the Class A family of G protein-coupled receptors (GPCRs). Until recently, the AAR remained poorly characterised, in part due to its relatively low affinity for the endogenous agonist adenosine and therefore presumed minor physiological significance. However, the substantial increase in extracellular adenosine concentration, the sensitisation of the receptor and the upregulation of AAR expression under conditions of hypoxia and inflammation, suggest the AAR as an exciting therapeutic target in a variety of pathological disease states. Here we discuss the pharmacology of the AAR and outline its role in pathophysiology including ischaemia-reperfusion injury, fibrosis, inflammation and cancer.
腺苷 A 受体 (AAR) 是属于 G 蛋白偶联受体 (GPCR) 家族 A 类的四种腺苷受体亚型之一。直到最近,AAR 的特征仍然很差,部分原因是它对内源性激动剂腺苷的亲和力相对较低,因此推测其生理意义较小。然而,细胞外腺苷浓度的大幅增加、受体的敏化以及缺氧和炎症条件下 AAR 表达的上调,表明 AAR 是多种病理疾病状态下令人兴奋的治疗靶点。在这里,我们讨论了 AAR 的药理学,并概述了它在病理生理学中的作用,包括缺血再灌注损伤、纤维化、炎症和癌症。